2023
DOI: 10.21203/rs.3.rs-2589347/v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Hematologic Toxicities and its Determinants among Breast Cancer Patients Treated with Doxorubicin-Cyclophosphamide Followed by Paclitaxel Regimen in Cancer Centers: Retrospective Cohort Study

Abstract: Background Clinically, chemotherapy induced neutropenia, febrile neutropenia, thrombocytopenia and anemia were the common toxicities among breast cancer patients treated with doxorubicin-cyclophosphamide followed by paclitaxel regimen. Those toxicities may lead to chemotherapy dose modification, delay and discontinuation that may substantially compromise therapeutic outcomes. Objective To assess hematologic toxicities and its determinants among breast cancer patients treated with doxorubicin-cyclophosphamid… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 38 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?